Afluria Market Report 2026

Afluria Market Overview

• The Afluria market growth in the historic period has been driven by recurring seasonal influenza outbreaks, public health vaccination policies • Market expansion is supported by growth in preventive healthcare awareness, increasing vaccination coverage targets • Growth Driver: Rising Influenza Prevalence Boosts Afluria Vaccine Market Growth • Market Trend: Innovative Solutions In The Influenza Vaccine Market Enhanced Growth • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Afluria Market?

Afluria is an inactivated influenza vaccine designed to protect against infections caused by specific strains of the influenza virus. Approved for individuals aged 6 months and older, it is administered via injection and helps stimulate the immune system to produce antibodies. Annual vaccination is recommended to ensure effective protection against seasonal flu outbreaks. The main formulations of afluria are pre-filled syringes and multi-dose vials. Pre-filled syringes offer a single-dose option for flu vaccines, ensuring accuracy and ease of use. They are commonly used in outpatient clinics and pharmacies to streamline administration. These syringes reduce contamination risk and support efficient immunization efforts. The clinical indication includes Influenza Prevention and is distributed through hospitals and clinics, retail pharmacies, and government suppliers and utilized by end users such as pediatric, adult, and geriatric.

What Is The Afluria Market Growth Forecast?

The growth in the forecast period can be attributed to growth in preventive healthcare awareness, increasing vaccination coverage targets, expansion of retail pharmacy immunization, improved cold chain logistics, rising geriatric population. Major trends in the forecast period include rising demand for seasonal influenza vaccination, expansion of adult and pediatric immunization programs, increased focus on preventive healthcare, growth in government-supported vaccination campaigns, improved vaccine distribution infrastructure.

Global Afluria Market Segmentation

1) By Formulation: Pre-Filled Syringes, Multi-Dose Vials 2) By Clinical Indication: Influenza Prevention 3) By Distribution Channel: Hospitals And Clinics, Retail Pharmacies, Government Supplier 4) By End Users: Pediatric, Adult, Geriatric

What Are The Drivers Of The Afluria Market?

The growing prevalence of influenza is expected to propel the growth of the afluria market going forward. Influenza, commonly known as the flu, is an infectious respiratory disease caused by influenza viruses that can lead to mild to severe illness, with symptoms including fever, cough, sore throat, body aches, and fatigue. The increasing prevalence of influenza is attributed to factors such as heightened public awareness of the disease, rising incidence rates from virus mutations, and greater demand for vaccinations, especially among vulnerable groups like the elderly. Afluria is used as a vaccine to prevent influenza by stimulating the immune system to produce antibodies against the flu virus. For instance, in November 2024, according to a report published by the UK Health Security Agency, a UK-based government agency, as of October 16, 2024, influenza positivity rose to 2.3% in week 41, up from 2% the previous week, with the highest rates (5.1%) seen in those aged 5 to 14 years. Therefore, the growing prevalence of influenza is driving the growth of the afluria industry. The growing geriatric population is expected to propel the growth of the afluria market going forward. The geriatric population refers to individuals who are typically aged 65 and older and characterized by unique health needs and challenges associated with aging. The geriatric population is growing due to a combination of declining fertility rates and increasing life expectancy, resulting in a larger proportion of older individuals within the overall population. The geriatric population, which is particularly vulnerable to severe illness and mortality from influenza, necessitates effective vaccination strategies such as afluria to protect older adults and reduce flu-related health complications. For instance, in July 2024, according to a report published by the House of Commons Library, a UK-based government agency, the UK's population is aging, with around 12.7 million people aged 65 and over in 2022, accounting for 19% of the total population, and this number is expected to rise to 22.1 million, or 27% of the population, by 2072. Therefore, the growing geriatric population is driving the growth of the afluria industry.

Key Players In The Global Afluria Market

Major companies operating in the afluria market are CSL Seqirus

Global Afluria Market Trends and Insights

Major companies operating in the afluria market are focusing on developing innovative solutions such as nano-sized particle-based vaccines to enhance vaccine efficacy, stability, and targeted delivery. A nanoparticle-based vaccine refers to a formulation that uses ultra-small particles in the nanometer range to deliver antigens more efficiently and strengthen immune response. For instance, in March 2024, Cadila Pharmaceuticals Ltd., an India-based pharmaceutical company, launched the Cadiflu Tetra Vaccine, an advanced quadrivalent influenza vaccine designed to prevent seasonal influenza. The vaccine targets four influenza virus strains, including subtypes A and B, and integrates key proteins such as hemagglutinin (HA), neuraminidase (NA), and matrix 1 (M1) in a single formulation. This approach offers broader protection, improved immunogenicity, and a superior safety profile compared to traditional influenza vaccines.

Regional Insights

North America was the largest region in the afluria market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Afluria Market?

The afluria market consists of sales of afluria quadrivalent, and afluria trivalent. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Afluria Market Report 2026?

The afluria market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the afluria industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.